Blood preservation with STBS - gateway to personalized medicine

Biosafety level two laboratory enables SPARK TECH team to work with agents associated with human disease e.g. pathogenic or infectious organisms posing a moderate hazard, including COVID-19.

On November 18, 2021 will take palce invited on-line presentation of SPARK TECH entitled „SME Instrument – tips for applicants in EIC Accelerator EU funding scheme”.

First patent in our portfolio

Publication of Spark-Tech patent application in China.

On May 2019 Spark-Tech signed grant agreament with The National Centre for Research and Development to develop Spark-Tech Biobanking System (STBS). Value of this project is 11 300 248,31 PLN (2,6 mln EURO) with EU contribution of 8 836 058,10 PLN (2,2 mln EURO). Project will be conducted from June 2019 to May 2021. https://www.ncbr.gov.pl/fileadmin/POIR/3_1.1.1_2018_MSP_Seal_of_Excellence/lista_rankingowa_listopad_2018_SOE.pdf Spark-Tube…
Przeczytaj więcej

Spark-Tech Biobanking System (STBS) and its components pictured in red cross are to streamline diagnostic effort. Figure illustrates that specimen collection (green frame) can be done simply in various conditions. Later STBS in automated fashion separates and preserves patient samples which can be send to analyses remotely (blue frame).    

Spark-Tech signed an agreement to lead implementation of National project awarded to Katarzyna Marzec PhD within Lider program http://jcet.eu/new_en/research/#012 . Spark-Tech will be responsible for IPR and commercial aspects of project results.

Publication of Spark-Tech patent application in United States

Publication of Spark-Tech patent application in China